EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE Drug Patent Profile

« Back to Dashboard

When do Emtricitabine And Tenofovir Disoproxil Fumarate patents expire, and when can generic versions of Emtricitabine And Tenofovir Disoproxil Fumarate launch?

Emtricitabine And Tenofovir Disoproxil Fumarate is a drug marketed by Hetero Labs Ltd Iii and is included in one NDA.

The generic ingredient in EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is emtricitabine; tenofovir disoproxil fumarate. There is one drug master file entry for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Emtricitabine And Tenofovir Disoproxil Fumarate

A generic version of EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE was approved as emtricitabine; tenofovir disoproxil fumarate by TEVA PHARMS USA on June 8^th, 2017.

Summary for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	5
Clinical Trials:	187
DailyMed Link:	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE at DailyMed

Recent Clinical Trials for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
HIV Prevention Trials Network	PHASE2
Abdelrahman Mahmoud	PHASE2
Instituto Mexicano del Seguro Social	PHASE4

See all EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE clinical trials

Pharmacology for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

US Patents and Regulatory Information for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd Iii	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	201806-001	Oct 7, 2021	AB	RX	No	No

Emtricitabine and Tenofovir Disoproxil Fumarate Market Dynamics, Patent Estate and Financial Trajectory

Last updated: September 28, 2026

Emtricitabine/tenofovir disoproxil fumarate, commonly abbreviated FTC/TDF and marketed originally as Truvada, has moved from a premium branded HIV therapy to a low-cost generic product. Gilead Sciences built a multibillion-dollar franchise around Truvada, first for HIV treatment and later for pre-exposure prophylaxis, or PrEP. Generic entry, the migration of patients to Biktarvy and Descovy, and public-sector purchasing have sharply reduced the branded product’s revenue.

The drug remains commercially important because it is inexpensive, clinically established, included in major HIV and PrEP guidelines, and widely available through generic manufacturers. Its principal value is now volume, access and public-health use rather than brand pricing power.

What is emtricitabine and tenofovir disoproxil fumarate used for?

FTC/TDF combines two nucleoside or nucleotide reverse transcriptase inhibitors:

Attribute	Details
Active ingredients	Emtricitabine and tenofovir disoproxil fumarate
Original brand	Truvada
Originator	Gilead Sciences
FDA approval	2004 for combination antiretroviral treatment
PrEP approval	2012 for reducing sexually acquired HIV-1 infection risk
Dosage form	Oral fixed-dose tablet
Main markets	HIV treatment, HIV PrEP, global public-health programs
Main competitors	Biktarvy, Genvoya, Descovy, generic FTC/TDF, long-acting cabotegravir
Generic status	Available in the United States and international markets

Truvada is used with other antiretroviral agents for HIV-1 treatment. It is also approved for HIV PrEP in combination with safer-sex practices. Descovy, which contains emtricitabine and tenofovir alafenamide, competes directly in HIV treatment and PrEP but is not approved for people at risk through receptive vaginal sex in the United States as of the latest FDA labeling framework. That limitation has supported continued FTC/TDF demand in some PrEP populations.

When did Truvada lose exclusivity?

Truvada lost effective commercial exclusivity in stages rather than on a single date.

Event	Approximate timing	Commercial effect
FDA approval of Truvada	2004	Created the branded combination market
FDA approval for PrEP	2012	Opened a major second indication
Core product patent expirations	Late 2010s to early 2020s	Reduced blocking protection
Gilead generic settlements	2014 onward	Established controlled generic-entry dates
U.S. generic FTC/TDF launches	2020	Accelerated branded price and volume erosion
Truvada PrEP exclusivity erosion	2020 onward	Shifted demand toward generic and public-sector supply
Current market structure	2024 onward	Generic-dominated, with branded use concentrated in selected channels

Gilead entered settlement agreements with generic manufacturers, including Teva, that permitted generic versions of Truvada and related products to enter before the ultimate expiration of all relevant patent rights. The settlement structure helped define the timing of generic competition while protecting a period of branded revenue.

The practical loss of exclusivity occurred when multiple generic suppliers began selling FTC/TDF in the United States in 2020. By then, Gilead had already shifted strategic emphasis toward Biktarvy, Descovy and other newer products.

What patents protected emtricitabine and tenofovir disoproxil fumarate?

The patent estate covered the active ingredients, combinations, formulations and methods of use. The most commercially relevant protection involved tenofovir disoproxil fumarate, the fixed-dose FTC/TDF combination and HIV prevention uses.

Patent category	Protected subject matter	Commercial relevance
Active-ingredient patents	Emtricitabine and tenofovir prodrug chemistry	Established early exclusivity
Combination patents	FTC/TDF fixed-dose combinations	Supported Truvada protection
Formulation patents	Tablet composition, excipients and manufacturing parameters	Created narrower barriers to copying
Method-of-treatment patents	HIV treatment with FTC/TDF-containing regimens	Supported labeling and enforcement
PrEP method patents	Use of FTC/TDF to reduce HIV acquisition risk	Became central to later litigation
Manufacturing patents	Processes for producing active pharmaceutical ingredients and tablets	Can delay or complicate supply entry

The principal patent risks for generic manufacturers were not limited to the basic drug compounds. A generic applicant needed to assess active-ingredient patents, combination patents, Orange Book-listed patents and method-of-use patents. The commercial strength of each patent depended on claim scope, remaining term, validity, enforceability and whether a generic product’s label could avoid the claimed use.

The PrEP-related patent dispute was especially important because the prevention indication extended the commercial value of FTC/TDF beyond the original HIV-treatment market.

What is the Orange Book status of Truvada?

Truvada was approved under FDA New Drug Application 021752. The Orange Book historically listed patents associated with the product, including patents directed to tenofovir disoproxil fumarate, emtricitabine combinations and relevant uses.

The economic effect of the Orange Book listings declined after generic companies filed Paragraph IV certifications and reached settlements with Gilead. Generic applicants could challenge listed patents by asserting that the patents were invalid, unenforceable or not infringed. They could also use Paragraph III certifications, which accept delayed launch until patent expiration.

The Orange Book does not capture every relevant patent affecting market entry. Manufacturing patents, non-listed patents and litigation involving government-funded PrEP patents can remain commercially relevant even when the primary product patents have expired.

Which companies challenged Truvada patents?

Generic competition involved major pharmaceutical manufacturers and specialized generic suppliers. The most commercially relevant challengers included Teva and other companies that filed abbreviated new drug applications for FTC/TDF or related products.

Paragraph IV litigation and settlement activity allowed generic manufacturers to negotiate launch dates rather than wait for every patent to expire. The resulting settlements limited immediate litigation uncertainty but also gave Gilead visibility into the timing of generic erosion.

The competitive field now includes:

• Teva and other U.S. generic manufacturers.
• Large international suppliers serving Europe and emerging markets.
• Contract manufacturers supplying public-health programs.
• Regional companies producing WHO-prequalified or nationally approved versions.
• Brand and specialty suppliers serving Medicaid, PrEP clinics and government contracts.

What patent litigation affected Truvada and HIV PrEP?

The most consequential later dispute involved Gilead’s HIV PrEP patents and the U.S. government.

The U.S. Department of Health and Human Services alleged that Gilead infringed government-owned patents relating to HIV PrEP and argued that the company had benefited from federally funded research. Gilead denied liability and challenged the government’s position. The dispute concerned patents including U.S. Patent Nos. 9,044,509 and 9,579,333, which were associated with PrEP methods.

The case had three commercial implications:

1. It increased legal uncertainty around the value of the PrEP indication.
2. It highlighted the distinction between product patents and government-funded method-of-use patents.
3. It placed additional pressure on Gilead while generic FTC/TDF was already entering the market.

Gilead and HHS settled the dispute in 2023. The settlement reduced ongoing litigation exposure but did not restore Truvada’s lost exclusivity or reverse generic entry.

What formulation patents protect FTC/TDF?

Formulation patents can cover tablet composition, excipient ratios, stability, coating, dissolution and manufacturing processes. These patents usually provide narrower protection than active-ingredient patents.

For FTC/TDF, formulation protection has limited the ability of a generic company to copy the exact branded presentation. It has not prevented market substitution where a generic applicant can demonstrate bioequivalence using a different formulation.

Formulation patents are commercially more important when:

• The product has difficult stability characteristics.
• The active ingredients have different solubility or compression properties.
• The dosage form requires specialized coating or release characteristics.
• The originator has protected a high-value combination with a narrow manufacturing process.

Generic FTC/TDF is an immediate-release oral tablet, which generally creates fewer technical barriers than an injectable, inhaled or extended-release product.

How strong is the patent estate for emtricitabine and tenofovir DF?

The patent estate was strong during the initial life-cycle period but is weak as a barrier to current generic competition.

Factor	Assessment
Core product maturity	High
Remaining broad exclusivity	Limited or expired in major markets
Formulation complexity	Moderate to low
Generic manufacturing difficulty	Moderate
Method-of-use relevance	Still material for PrEP
Litigation leverage	Reduced after generic entry
Global access barriers	Low to moderate
Risk of biosimilar competition	Not applicable

The combination benefited from a strong early franchise because HIV therapy requires chronic daily use and adherence. That recurring demand supported premium pricing before generic entry. Once the core patents expired and multiple suppliers entered, the estate ceased to function as a reliable pricing barrier.

How does FTC/TDF compare with Descovy and Biktarvy?

Product	Composition	Primary commercial position	Main advantage	Main limitation
Truvada	FTC/TDF	Generic HIV treatment and PrEP	Low cost, broad familiarity, PrEP eligibility	Renal and bone safety concerns
Descovy	FTC/TAF	Branded HIV treatment and selected PrEP use	Improved renal and bone profile versus TDF	Higher price; narrower PrEP label
Biktarvy	Bictegravir/FTC/TAF	Leading branded HIV regimen	High efficacy, once-daily single-tablet regimen	No PrEP indication
Apretude	Long-acting cabotegravir	Injectable PrEP	Dosing every two months	Administration, logistics and cost
Generic FTC/TDF	FTC/TDF	Price-driven HIV and PrEP market	Lowest acquisition cost	TDF safety monitoring and adherence requirements

Biktarvy has been the principal branded successor to Truvada in HIV treatment. Descovy has captured patients for whom renal or bone safety is a concern and has provided Gilead with a premium alternative in selected PrEP populations. Apretude competes mainly in PrEP, where patients and payers may value long-acting administration.

What was the financial trajectory of Truvada?

Truvada generated multibillion-dollar annual revenue for Gilead before generic erosion. Revenue declined as patients moved to newer regimens and generic suppliers entered.

Period	Financial trajectory	Main drivers
2004-2011	Rapid growth	Expansion of HIV treatment and single-tablet therapy
2012-2016	High-value franchise	FDA PrEP approval and sustained treatment demand
2017-2019	Declining but material revenue	Biktarvy migration, Descovy positioning and patent pressure
2020-2021	Sharp erosion	U.S. generic entry and reduced branded demand
2022 onward	Mature generic market	Low branded volume, public-sector procurement and price competition

Gilead’s annual reports show that Truvada revenue declined materially before and after generic entry. Product-specific revenue was affected by several overlapping forces:

• Patients switching to Biktarvy.
• Patients switching from TDF to TAF-based regimens.
• Generic FTC/TDF substitution.
• Lower average selling prices.
• Government and pharmacy-benefit-manager pressure.
• Increased use of public-health purchasing channels for PrEP.

The financial value migrated from Truvada to the broader HIV portfolio. Biktarvy became the principal growth engine, while Descovy supported premium pricing in appropriate treatment and PrEP segments.

What is the current market structure for generic FTC/TDF?

The market is price competitive and fragmented across manufacturing, distribution and reimbursement channels.

United States

U.S. demand is divided among commercial insurance, Medicaid, Medicare, direct cash-pay channels and public-health programs. The availability of low-cost generic FTC/TDF has improved access to PrEP, but patient out-of-pocket costs can still vary based on dispensing channel and insurance design.

Federal and state programs are important purchasers. The 340B program, Medicaid and public-health clinics can obtain the product at substantially lower net prices than the historical branded price.

Europe

European markets have generally experienced earlier generic erosion because national health systems and centralized procurement negotiate aggressively. Price declines can be steep after loss of exclusivity, although tender structures may limit the number of active suppliers.

Emerging markets

Global HIV programs rely on generic fixed-dose combinations. The Medicines Patent Pool and other licensing mechanisms have supported broader access to antiretroviral medicines in low- and middle-income countries. Prices are determined by volume procurement, national tenders, donor funding and WHO or national quality requirements.

Are biosimilars a risk for FTC/TDF?

No. FTC/TDF is a small-molecule pharmaceutical, not a biologic. Biosimilar regulation does not apply. The relevant competitive risk is conventional generic substitution through abbreviated new drug applications or comparable national pathways.

The main barriers are bioequivalence, active pharmaceutical ingredient quality, manufacturing scale, regulatory compliance and procurement access. These barriers are lower than those associated with complex biologics but can still exclude smaller suppliers from regulated markets.

What generic launch scenarios exist for FTC/TDF?

The principal launch scenarios are:

Scenario	Market effect
Multi-supplier generic competition	Rapid price decline and stable supply
Two or three major suppliers	Moderate price erosion with periodic shortages possible
Public-sector tender concentration	Low prices but high supplier dependence
Branded residual demand	Limited use for patients or channels requiring Truvada
PrEP-driven volume growth	Higher unit demand despite low price
Shift to long-acting PrEP	Gradual pressure on oral PrEP volume

Generic entry does not eliminate demand. It changes the economics from high-margin branded chronic therapy to high-volume, low-margin pharmaceutical supply.

What licensing deals affected FTC/TDF access?

Gilead entered licensing and access arrangements for HIV medicines through direct agreements and organizations such as the Medicines Patent Pool. These arrangements facilitated generic production for designated countries and public-health programs.

Licensing reduced transaction costs for generic manufacturers and supported global scale. It also limited the ability of patent rights to sustain high prices in lower-income markets. The commercial result was broader product availability, but lower revenue per tablet.

Licensing and voluntary access arrangements were more important outside the United States than in the mature U.S. branded market. Their effect was strongest in countries where HIV treatment depends on donor procurement and generic fixed-dose combinations.

What revenue exposure remains for Gilead?

Direct Truvada revenue exposure is now limited. The larger strategic exposure is indirect:

• Loss of patients from Truvada to generic FTC/TDF.
• Cannibalization of older branded products by Biktarvy.
• PrEP competition from generic FTC/TDF and Apretude.
• Pricing pressure on Descovy.
• Public scrutiny of HIV medicine pricing and patent enforcement.
• Dependence on continued growth of the broader HIV portfolio.

Gilead’s HIV franchise remains financially significant, but its value is concentrated in newer products. Truvada is now primarily a legacy asset that supports patient access, generic volume and public-health programs.

Key Takeaways

• FTC/TDF, originally sold as Truvada, is a mature oral HIV treatment and PrEP product.
• U.S. generic entry in 2020 ended meaningful branded exclusivity.
• The product’s patent estate covered active ingredients, fixed-dose combinations, formulations and PrEP methods.
• PrEP-related patents produced significant litigation involving Gilead and HHS.
• The 2023 HHS-Gilead settlement reduced litigation uncertainty but did not restore market exclusivity.
• Biktarvy and Descovy replaced Truvada as Gilead’s principal branded growth products.
• Generic FTC/TDF remains commercially important because of low cost, broad clinical use and public-health procurement.
• Biosimilar risk is irrelevant because FTC/TDF is a small-molecule drug.
• Future value is driven by volume, tenders, PrEP access and supply reliability rather than branded pricing.

FAQs About Emtricitabine and Tenofovir Disoproxil Fumarate

Is generic FTC/TDF therapeutically equivalent to Truvada?

FDA-approved generic versions must demonstrate bioequivalence and meet applicable quality requirements. They are generally substitutable under state pharmacy laws, subject to product-specific substitution rules.

Why did patients switch from Truvada to Biktarvy?

Biktarvy is a complete once-daily HIV regimen with a favorable efficacy and tolerability profile. It also avoids the need to combine Truvada with a separate third antiretroviral agent for treatment.

Can FTC/TDF still be used for HIV PrEP?

Yes. FTC/TDF remains an FDA-approved PrEP option for eligible individuals when used as directed and combined with appropriate HIV testing and clinical monitoring.

What is the main safety concern with tenofovir disoproxil fumarate?

Long-term TDF exposure can affect renal function and bone mineral density in some patients. Clinicians assess patient-specific risks and may consider tenofovir alafenamide or non-tenofovir options where appropriate.

Will long-acting injectable PrEP eliminate demand for oral FTC/TDF?

No. Injectable cabotegravir may capture some patients, but oral FTC/TDF remains important because of cost, availability, patient preference, prescribing familiarity and public-sector procurement.

References

1. Gilead Sciences, Inc. (2024). 2023 annual report. Gilead Sciences.

2. U.S. Food and Drug Administration. (2004). Truvada: FDA approval history and prescribing information. FDA.

3. U.S. Food and Drug Administration. (2012). FDA approves first drug for reducing the risk of sexually acquired HIV infection. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Department of Health and Human Services. (2023). United States v. Gilead Sciences, Inc.: HIV pre-exposure prophylaxis patent litigation settlement materials. HHS.

6. Medicines Patent Pool. (2024). Licensing and access to HIV medicines. Medicines Patent Pool.

7. U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,642,245: Nucleotide analogues. USPTO.

8. U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,044,509: Methods for preventing HIV infection. USPTO.